Celecoxib News and Research

RSS

Antiangiogenic and anti-inflammatory drugs: are they safe?

Since Rofecoxib (Vioxx) was withdrawn from the worldwide market based on the safety findings of the Adenomatous Polyp Prevention on Vioxx (APPROVe) study, the uncertainty around the cardiovascular safety of NSAIDs and COX-2 inhibitors remains and leaves practitioners with difficult management decisions for the hundreds of millions of patients worldwide who continue to require pain-relieving therapy to maintain an acceptable quality of life.

1 Sep 2008

Ibuprofen found to reduce the risk of Alzheimer's

A large study by scientists in the U.S. has revealed that the long-term use of ibuprofen may reduce the risk of a person developing Alzheimer's disease.

6 May 2008

Ibuprofen linked to lower risk of Alzheimer's

Long-term use of ibuprofen and other drugs commonly used for aches and pains was associated with a lower risk of Alzheimer's disease, according to a study published in the May 6, 2008, issue of Neurology, the medical journal of the American Academy of Neurology. Previous studies have shown conflicting results, but this is the longest study of its kind.

5 May 2008

Lipitor and Celebrex combined may halt prostate cancer

Researchers at Rutgers' Ernest Mario School of Pharmacy have shown that administering a combination of the widely used drugs Celebrex (celecoxib, a nonsteroidal anti-inflammatory drug) and Lipitor (atorvastatin, a cholesterol lowering drug) stops the transition of early prostate cancer to its more aggressive and potentially fatal stage.

15 Apr 2008

Cancer prevention

Tapping into a growing body of knowledge about the origins and progression of cancer, researchers are now developing and testing new preventive therapies to stop it in its tracks.

15 Apr 2008

COX-2 expression is marker for cancer development in some benign breast biopsies

It's a good news, bad news situation. Some women who have a breast biopsy are told that while they don't have cancer, they do have atypical hyperplasia -- cells that aren't quite normal and might become cancerous someday.

12 Mar 2008

Risks of CVD for COX-2 inhibitors lower than previously reported

In an article published in the March issue of the Journal of Cardiovascular Pharmacology and Therapeutics, researchers from Florida Atlantic University (FAU) assess the totality of evidence, including strengths and limitations of different types of evidence contributing to the debate about cardiovascular disease (CVD) risks of cyclooxygenase-2 (COX-2) inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs).

27 Feb 2008

Celecoxib offers promise for premature babies

Scientists have found evidence that the cox-2 inhibitor celecoxib, a common pain reliever used to treat arthritis, may offer a new way to reduce the risk of the most common cause of brain damage in babies born prematurely.

18 May 2007

Some NSAIDs may be better suited to treating cancer

Until recently, nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin and celecoxib (sold as Celebrex), were being hailed as promising cancer prevention drugs.

18 May 2007

Naproxen and celecoxib do not prevent Alzheimer's disease

Over-the-counter pain medication naproxen and prescription pain reliever celecoxib do not prevent Alzheimer's disease, according to a study published April 25, 2007, in the online edition of Neurology, the scientific journal of the American Academy of Neurology.

26 Apr 2007

Time for FDA to set the record straight on common painkillers

The U.S. Food and Drug Administration (FDA) has caused an unnecessary scare about some pain relievers by adding a warning to drugs that are safe, says Curt Furberg, M.D., Ph.D., from Wake Forest University School of Medicine.

25 Apr 2007

Four genes found to drive spread of breast cancer to the lungs

Studies of human tumor cells implanted in mice have shown that the abnormal activation of four genes drives the spread of breast cancer to the lungs.

12 Apr 2007

Inhaled Celecoxib shows new promise for lung cancer treatment

In recent years, Cycloxygenase (COX)-2 has emerged as a therapeutic target for the prevention and treatment of various types of cancers.

6 Mar 2007

Green tea and COX-2 inhibitors combine to slow growth of prostate cancer

Drinking a nice warm cup of green tea has long been touted for its healthful benefits, both real and anecdotal. But now researchers have found that a component of green tea, combined with low doses of a COX-2 inhibitor, could slow the spread of human prostate cancer.

1 Mar 2007

Common painkiller helps against child cancer

Neuroblastoma is a form of cancer that develops in the nervous system and it affects small children more commonly than any other tumour type.

5 Feb 2007

New class of super NSAIDs

Building on previous work, researchers at the University of Pennsylvania School of Medicine have found that deleting an inflammation enzyme in a mouse model of heart disease slowed the development of atherosclerosis.

12 Sep 2006

Celebrex shown to reduce incidence of potentially pre-malignant colorectal polyps

An international team of scientists reports that a single 400-milligram daily dose of celecoxib, commonly called Celebrex. and manufactured by Pfizer, significantly reduced recurrence of adenomas, or pre-malignant colon tumors - within three years of previous adenoma removal.

30 Aug 2006